Menu UF Health Home Menu
 

Current Funding

The strength of our research team here in the Department of Ophthalmology is highlighted, in part, by their funding.

Funding by Researcher

John Ash, Ph.D.

  • NIH/NEI,  R01 EY016459-05  (Ash)
    Cytokine Regulation of Photoreceptor Gene Expression
    9/01/2010-8/31/2013
  • Foundation Fighting Blindness (Ash)
    “Using AAV-STAT3 and AAV-PIM1 vectors to induce broad-spectrum protection of photoreceptors and RPE”
    6/1/2013-5/31/2016

Sanford L. Boye, M.S.

  • “Retinoschisin Mouse Model Re-derivation and Efficacy Testing of AAV-RS1” (SL Boye)
    Funding Agency: AGTC
    Dates: 6/1/2014-5/31/2015
  •  “Evaluation of rAAV2tYF-CB-hRS1 Tox/BD Drug product for Transduction Efficiency and Rescue of ERG Responses in RS1 Knock-out Mice” (SL Boye and Hauswirth)
    Funding Agency: AGTC
    Dates: 3/4/2014-3/6/2015
  •  “Toxicology, Biodistribution and Efficacy Study of rAAV2tYF-CB-hRS1” (subproject- SL Boye)
    Funding Agency: Applied Genetics Technologies Corporation (AGTC)
    Dates: 12/10/13-12/09/14
  • “Gene Therapy for LCA1” (SE Boye)
    Funding Agency: Genzyme-Sanofi
    Dates: 3/1/2014-2/28/2016
  • “Vision Research Core” (P30EY021721)
    Funding Agency: NIH/National Eye Institute
    Role: Senior personnel, modules supervisor, (PI, Hauswirth)
    Dates: 8/1/2011-7/31/2016

Shannon E. Boye, Ph.D.

  • RO1EY024280 (SE Boye)
    “Developing Efficient AAV Vectors for Photoreceptor Targeting via the Vitreous”
    6/01/14-5/31/19
  • Genzyme/Sanofi (SE Boye)
    “Gene Therapy for LCA1”
    4/01/14-3/31/17
  • Foundation Fighting Blindness (SE Boye)
    Individual Investigator Research Award
    Targeting foveal cones using novel delivery methods and novel AAV serotypes
    6/01/12-6/01/15
  • Foundation Fighting Blindness (SE Boye)
    Individual Investigator Award
    “Dual AAV vector-mediated therapy for Myosin7A Usher syndrome (USH1B)”
    8/01/14-7/31/16
  • Foundation Fighting Blindness (Hauswirth and SE Boye)
    Wynn Gund TRAP (Translational Research Acceleration Program) Award
    Gene Therapy for LCA1
    10/1/10-9/30/15
  • AGTC Inc. Sponsored Research Agreement (SE Boye)
    10/1/14-9/30/16
  • AGTC Sponsored Research Agreement (Zolotukhin and SE Boye)
    10/1/14-9/30/17
  • Overstreet Endowment (Tuli)
    University of Florida Foundation
    Research in Age-Related Macular Degeneration
    6/1/2014-present

William W. Hauswirth, Ph.D.

  •  Grant Identifier: R24 EY022023 (Hauswirth)
    6/01/13-5/31/18
    Sponsor: NEI
    Title of Grant: rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research Studies
  • Grant Identifier: P30-EY021721 (Hauswirth)
    8/01/11-7/31/16
    Sponsor: NEI
    Title of Grant: Vision Research Center
  • Grant Identifier: NA (Hauswirth)
    1/01/13-12/31/16
    Sponsor: Macular Vision Research Foundation
    Title of Grant: Gene Therapy for Blue Cone Monochromacy (BCM)
  • Grant Identifier: NA (Hauswirth)
    7/1/13-6/30/16
    Sponsor: Elden Family Foundation
    Title of Grant: Gene Therapy for Ush3A
  • Grant Identifier: 2011445 (Banin)
    10/01/12-9/30/16
    Sponsor: US Israel Binational Science Foundation
    Title of Grant: Gene Therapy Using Novel Viral Vectors in the CNGA3 Sheep Model of Achromatopsia
  • Grant Identifier: TA-GT-0911-0559-AGTC-WG (Washer)
    10/01/12-9/30/16
    Sponsor: Foundation Fighting Blindness
    Title of Grant: AAV-based Gene Therapy for X-linked Retinoschisis
  • Grant Identifier: R24 EY022012 (Beltran)
    3/01/12-2/28/16
    Sponsor: NEI
    Title of Grant: Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
  • Grant Identifier: R01 EY017549 (Aguirre)
    9/30/06-7/31/15
    Sponsor: NEI
    Title of Grant: Translational Research for Retinal Degeneration Therapies
  • Grant Identifier: C-GT-071-0536-UFL04 (Weleber)
    7/01/11-6/30/16
    Sponsor: Foundation Fighting Blindness
    Title of Grant: OHSU Research Center for the Study of Retinal Degenerations
  •  Grant Identifier: U10-EY017280 (Jacobson)
    9/30/06-7/31/15
    Sponsor: NEI
    Title of Grant: Clinical Trials of Gene Therapy for Leber Congenital Amaurosis Type 2
  •  Grant Identifier: C-GT-0812-0590-UFL03 (Jacobson)
    8/1/12-7/31/17
    Sponsor: Foundation Fighting Blindness
    Title of Grant: FFB Center at the Scheie Eye Center
  •  Grant Identifier: FFB TA-GT-0611-0526-UF (Lewin)
    6/30/14-6/29/17
    Sponsor: Foundation Fighting Blindness
    Title of Grant: RNA Replacement Therapy for ADRP
  •  Grant Identifier: R01 EY012978 (Nirenberg)
    2/1/13-1/31/17
    Sponsor: NEI
    Title of Grant: Population Coding in the Retina

Qiuhong Li, Ph.D.

  • NIH RO1 (Li)
    Renin Angiotensin System in Pathogenesis of Diabetic Retinopathy
    1/1/2012-12/31/2015
  • NIH RO1 (Grant/Raizada)
    Vascular Reparative Mechanism by ACE2/Ang-(1-7) in Diabetes
    7/1/2011 – 6/30/2016

Daniel M. Lipinski, D.Phil.

  • Juvenile Diabetes Research Foundation (JDRF) Innovative Award (1-PNF-2014-120-A-N)
    Validation of a novel AAV vector for targeted gene therapy to prevent vascular complications of diabetic retinopathy (PI: Lipinski)
    5/01/2014-10/31/2015

Jijing Pang, MD, Ph.D.

  • 2014 UF Faculty Enhancement Opportunity Award
  • Macula Vision Research Foundation (Hauswirth and Pang)
    “Vitreal delivery of novel AAV vectors for blue cone monochomacy (BCM)”
    01/01/14 – 12/31/16
  • R21EY023543 (Pang)
    “Vitreal delivery of novel AAV vectors for CNGA3 achromatopsia cone gene therapy”
    08/01/2013 – 07/31/2015
  • UF and WMU agreement (Pang) to design, produce and deliver the AAV vectors to WMC
    07/01/2013 – 12/31/2017
  • International collaboration project by The Ministry of Science and Technology of China 2010DFB33430 (China PI: Fangtian Dong, US PI: Jijing Pang)
    “Genetic diagnosis and gene therapy of inherited retinal degeneration in China”
    01/01/2011 to 12/31/15

Clay Smith, Ph.D.

  • NIH National Eye Institute/ R01 EY014864-06 Smith (PI)
    Arrestin Migration in Photoreceptors: Mechanism/Function”
    08/01/11 – 6/30/15
  • NIH National Eye Institute (Smith)
    “Training in Vision Sciences”
    01/01/10-12/31/14
  • Overstreet Foundation (Tuli)
    University of Florida Foundation Research in Age-Related Macular Degeneration
    10/01/11-present
  • Shaler-Richardson Professorship (Smith)
    College of Medicine, Univ. of Florida
    4/1/09-present

Sonal Tuli, M.D.

  • NIH RO1 – EY 05587-25  (Co-I)
    Regulation of Stromal Wound by Growth Factors
  • CTSI Training Award (mentor)
    8/2014-8/2015